NEKTAR THERAPEUTICS (NKTR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US6402683063
NEKTAR THERAPEUTICS financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 55.23 m USD |
| Gross profit | 55.23 m USD |
| Operating income | -140.10 m USD |
| EBIT | -174.65 m USD |
| Net income | -164.08 m USD |
| Diluted EPS – continuing operations | -9.73 USD |
Full history since 1994, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About NEKTAR THERAPEUTICS
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorporated in 1990 and is headquartered in San Francisco, California.
More stocks
- Chongqing Zaisheng Tech Corp (603601.SS)
- COMMUNITY TRUST BANCORP INC /KY/ (CTBI)
- Ventec International Group Co Ltd (6672.TW)
- DBV Technologies S.A. (DBVT)
- Superior Plus Corp (SPB.TO)
- Silicon2 Co. Ltd. (257720.KQ)
- Gansu Jiu Steel Group Hongxing Iron & Steel Co Ltd (600307.SS)
- West China Cement Ltd (2233.HK)
- Taiwan Fertilizer Co Ltd (1722.TW)
- LB PHARMACEUTICALS INC (LBRX)
- Guangdong High Dream Intellectualized Machinery Co Ltd Class A (300720.SZ)
- Gerresheimer (GXI.DE)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.